Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology

May 02, 2018   |   May 2018 Bond Updates
MENLO PARK, Calif., May 2, 2018 /PRNewswire/ -- Refuge Biotechnologies, Inc. ("Refuge"), a company leveraging gene engineering technologies to develop intelligent cell therapeutics programmed to make decisions inside of patients, today announced the closing of a $25 million Series B...

View more at: https://www.prnewswire.com/news-releases/refuge-biotechnologies-completes-25-million-series-b-financing-appoints-cso-to-advance-the-development-of-intelligent-cell-therapies-in-oncology-300640708.html
 
Related News
Home| About us | Contact us http://www.bondupdatesdailynews.com/